Alexander Armour, DO
Interventional Cardiology · Amarillo, TXNPI 1417113945
Payments from drug & device makers
Across 747 payments — averaging $50.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$12K
- Abiomed$7K
- Abbott$6K
- Avinger Inc.$5K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Endologix LLC$1K
- plus $5K from 24 others
What the payments were for
- Travel & lodging$6,14717%
- Food & beverage$30,24583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 218 | $11,559 |
| Abiomed | 137 | $7,167 |
| Abbott | 185 | $6,336 |
| Avinger Inc. | 30 | $5,207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $1,171 |
| Endologix LLC | 3 | $1,148 |
| Philips North America LLC | 12 | $681 |
| Penumbra, Inc. | 10 | $667 |
| Johnson & Johnson | 32 | $435 |
| Cook Medical LLC | 18 | $374 |
| Cordis US CORP. | 18 | $340 |
| Biotronik Inc. | 8 | $264 |
| Shockwave Medical, Inc | 7 | $256 |
| Silk Road Medical, Inc. | 4 | $244 |
| Imperative Care, Inc | 3 | $243 |
| AstraZeneca | 15 | $221 |
| Boston Scientific | 10 | $220 |
| BD | 2 | $216 |
| E.r. Squibb & Sons, L.L.C. | 3 | $149 |
| Atricure, Inc. | 1 | $137 |
| Chiesi USA, Inc. | 1 | $99 |
| Amgen | 6 | $95 |
| Pfizer | 3 | $47 |
| Cardiovascular Systems Inc. | 4 | $42 |
| Medtronic(2 entities) | 2 | $41 |
| Novartis | 2 | $38 |
| Bard Peripheral Vascular, Inc. | 1 | $35 |
| Terumo Medical Corporation | 1 | $26 |
| Teleflex LLC | 1 | $20 |
| EKOS Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANTHERIS$4,207
- Impella$2,667
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,056
- Torus Stent Graft System$1,041
- ENDOCROSS Device$1,041
- XIENCE SKYPOINT$223
- Indigo System$219
- Supera peripheral stent system$204
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$151
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- SYMPHONY CATHETER$146
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$137
- RotarexS 6 F x 135 cm$136
- Xience Sierra Coronary Stent$129
- CAMZYOS$125
- Indigo$122
- DRAGONFLY OPSTAR$115
- ESPRIT$112
- SAPIEN 3 Ultra RESILIA$109
- Alto Abdominal Stent Graft System$107
How this compares
$37,493 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 260 | $232,116 |
| EntrestoSacubitril/Valsartan | 64 | $46,673 |
| JardianceEmpagliflozin | 37 | $30,926 |
| BrilintaTicagrelor | 48 | $23,406 |
| XareltoRivaroxaban | 16 | $17,454 |
| Praluent PenAlirocumab | 28 | $13,609 |
| Repatha SureclickEvolocumab | 11 | $12,832 |
| ClopidogrelClopidogrel Bisulfate | 394 | $3,475 |
| Atorvastatin Calcium | 378 | $2,469 |
| Clonidine | 15 | $1,951 |
| Prasugrel Hcl | 34 | $1,450 |
| Losartan Potassium | 190 | $1,342 |
| Metoprolol Succinate | 120 | $1,325 |
| Rosuvastatin Calcium | 83 | $1,233 |
| Carvedilol | 239 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $232,116260 claims |
| NovartisEntresto | $38 | $46,67364 claims |
| AstraZenecaBrilinta | $221 | $23,40648 claims |
| Johnson & JohnsonXarelto | $435 | $17,45416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Amarillo
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.